AZN - Spark Newswire

2 minute read

Sierra Oncology Signs Exclusive Global In-Licensing Agreement With AstraZeneca For Novel BET Inhibitor To Expand Myelofibrosis Pipeline

Today, 11:45 AM

Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from

AZN

1 minute read

WHO Asks To Hold Off COVID-19 Vaccine Booster Shots Citing Inequality: Report

By Vandana Singh

Today, 11:45 AM

The World Health Organization (WHO) has called on wealthy nations to stop the distribution of COVID-19 booster shots, citing vaccine inequity worldwide. The World Health Organization called for a moratorium on booster shots until at least the end of September because of a shortfall in vaccine supplies to developing countries.

AZN

2 minute read

Movers

Thinking About Buying Stock In Lululemon, Lyft, AstraZeneca Or Clorox?

By Henry Khederian

Today, 11:45 AM

One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro. WIIMs are a one-sentence description as to why a stock is moving.

AZN

1 minute read

10 Biggest Price Target Changes For Wednesday

By Lisa Levin

Today, 11:45 AM

Baird boosted the price target for Lululemon Athletica Inc. (NASDAQ: LULU) from $395 to $435. Lululemon shares rose 0.2% to $408.30 in pre-market trading.

AYX

1 minute read

SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $69

By Benzinga Newsdesk

Today, 11:45 AM

SVB Leerink analyst Andrew Berens maintains AstraZeneca (NASDAQ:AZN) with a Outperform and raises the price target from $63 to $69.

AZN

1 minute read

Combining AstraZeneca, mRNA COVID-19 Vaccines Show Efficacy In Danish Study: Reuters

By Vandana Singh

Today, 11:45 AM

Combining AstraZeneca plc’s (NASDAQ:AZN) COVID-19 vaccine with a second dose from either Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) or Moderna Inc’s (NASDAQ:MRNA) shot provides “good protection,” Denmark’s…

AZN

1 minute read

AstraZeneca’ Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years

By Vandana Singh

Today, 11:45 AM

The FDA has approved AstraZeneca Plc’s (NASDAQ:AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE) who…

AZN

2 minute read

FDA
News

AstraZeneca Announced- Saphnelo Approved in the US for Moderate to Severe Systemic Lupus Erythematosus

By Charles Gross

Today, 11:45 AM

AstraZeneca's (NYSE: AZN) Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.1

AZN

2 minute read

Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report

By Shanthi Rexaline

Today, 11:45 AM

Pfizer, Inc. (NYSE: PFE) and Moderna, Inc. (NASDAQ: MRNA), which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.

AZN

2 minute read

Cashing COVID-19 Vaccine – AstraZeneca Or Pfizer

By Vandana Singh

Today, 11:45 AM

Today AstraZeneca plc (NASDAQ: AZN) released its second-quarter earnings with updated sales numbers for its COVID-19 vaccine; when compared to the big mRNA players, the numbers looked rather pale.

AZN

Feed Symbols: AZN